Functional reversal of Foxp3+T regulatory activity in patients enrolled in the Phase 3 ADAPT Trial evaluating Rocapuldencel-T for the treatment of patients with metastatic renal cell carcinoma (mRCC)
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2017）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined